Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. by Paul Germonpré, Tim Van den Wyngaert

Get full text

Trans-cyclooctene—a Swiss army knife for bioorthogonal chemistry: exploring the synthesis, reactivity, and applications in biomedical breakthroughs by Karuna Adhikari, Maarten Vanermen, Gustavo Da Silva, Tim Van den Wyngaert, Koen Augustyns, Filipe Elvas

Get full text

From SPECT/CT towards absolute quantification? - the case of unilateral condylar hyperplasia of the mandible by Stijn De Schepper, Gopinath Gnanasegaran, Wouter De Vos, Elke Van de Casteele, John C. Dickson, Tim Van den Wyngaert

Get full text

Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts by Yanina Dockx, Christel Vangestel, Tim Van den Wyngaert, Manon Huizing, Sven De Bruycker, Patrick Pauwels, Steven Staelens, Sigrid Stroobants

Get full text

18F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy. by Nils Helsen, Dessie Roothans, Bert Van Den Heuvel, Tim Van den Wyngaert, Danielle Van den Weyngaert, Laurens Carp, Sigrid Stroobants

Get full text